Physician profile
Roy James Renfro
NPI 1457323610
$941.20
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $128 · 2021: $197 · 2022: $95.80 · 2023: $53.30 · 2024: $17.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $241.69 | 2019-2024 | Euflexxa |
| Smith+Nephew, INC. | $235.92 | 2019 | |
| Radius Health, INC. | $74.11 | 2019-2021 | |
| Amgen INC. | $65.07 | 2020-2021 | |
| Relievant Medsystems, INC. | $47.12 | 2022-2023 | Intracept |
| Arteriocyte Medical Systems, INC. | $41.51 | 2019-2021 | |
| Bioventus LLC | $36.80 | 2019 | |
| Skeletal Dynamics INC | $36.00 | 2019 | |
| Endo Pharmaceuticals INC. | $30.23 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $28.60 | 2023 | Exparel, Zilretta, Iovera |
| Acelrx Pharmaceuticals, INC. | $18.90 | 2021 | |
| Depuy Synthes Sales INC. | $16.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.97 | 2022 | |
| Zimmer Biomet Holdings, INC. | $14.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.88 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Motive Health, INC. | $12.92 | 2019 | |
| Pacira Therapeutics, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Renfro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.